



Contacts:

Neuland Laboratories Limited
Ravikant Tadinada
+91 9885681385
RavikantTadinada@neulandlabs.com

US-Neuland Laboratories Inc.
Thomas Speace
President & CEO
(949) 218-1768
TSpeace@neulandlabs.com

US Media
BioCom Partners/Brandwidth Solutions
Barbara Lindheim
(212) 918-4650
blindheim@biocompartners.com

**NEULAND LABS LAUNCHES EXPANDED PEPTIDE MANUFACTURING CAPABILITIES AT
22ND AMERICAN PEPTIDE SYMPOSIUM**

***–Cost-Effective, High Quality Peptide Manufacturing Capabilities Now Expanded
to Commercial-Scale Projects Including APIs and Generic Peptides–***

–Learn More at Booth #37 at 2011 American Peptide Symposium in San Diego–

Hyderabad, India – June 22, 2011 – Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011.

“It is fitting that we formally launch our new commercial-scale peptide production service at this important gathering of leading peptide experts from around the world,” said M.K. “Mike” Anwer, Ph.D., vice president of research & development at Neuland Labs. “Neuland’s extensive experience in producing a variety of synthetic peptides parallels their increasing use as therapeutics and diagnostics, in antibody production and as research tools. Our expanded service provides rapid access to commercial quantities of affordable, high quality peptides from a company with a 27-year track record of consistently achieving the highest regulatory standards in global pharmaceutical production.”

Neuland Labs offers customers peptide production using standard sequential chemical peptide syntheses and segment condensation strategies. The company employs solid phase peptide synthesis procedures, as well as solution phase methods for shorter length peptides, and segment condensation and ligation techniques for very long peptides. Neuland researchers have also developed special methods to economically produce large quantities of high value peptide building blocks such as pseudoproline dipeptides.

Dr. Anwer added, “Our researchers have developed expertise in producing peptides of varying lengths and complexity. We are especially proud of our success in applying advanced methods for handling the aggregation and purification issues inherent in manufacturing long and complex peptides. Our diverse peptide customers also benefit from our value-added consultative services in analytical R&D and drug design, process development, optimization, validation, scale-up and the entire regulatory review and approval process. We work with companies of all sizes and are interested in exploring opportunities for collaborative efforts with a variety of potential partners.”

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing. Neuland scientists have developed more than 300 processes from bench scale to commercial production and have filed more than 400 drug master files worldwide. The company has a longstanding record of regulatory excellence, as demonstrated by seven successful FDA inspections since 1997, with the most recent completely free of any Form 483 investigational observations. Neuland’s cGMP certifications also include the TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001.

“Our new commercial-scale peptide manufacturing service reflects our ongoing strategy to leverage Neuland Labs’ innovative scientists, world-class manufacturing expertise, established infrastructure and reputation for quality to expand into new market segments. At a time when efficiency is critical to business success, we expect that our commitment to cost effectiveness, regulatory rigor and customer service will be a welcome option for peptide researchers and manufacturers,” noted Sucheth R. Davuluri, chief executive officer at Neuland Labs.

More information on Neuland’s peptide synthesis capabilities is available at Booth #37 at the 22nd American Peptide Symposium, which will be held June 25–30, 2011 at the Sheraton Hotel and Marina in San Diego, California.

About the American Peptide Society Symposium

Established in 1968 by the American Peptide Society, this biannual Symposium assembles national and international peptide scholars, researchers, educators and students together with corporate exhibitors and sponsors. The Symposium brings together investigators of varying backgrounds, with the goal of stimulating discussion, and catalyzing multidisciplinary collaborations in order to push the frontiers of peptide science. For more information, visit www.aps2011.org/

About Neuland Laboratories, Ltd.

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing. The company is committed to research, supporting a state-of-the-art R&D operation. Neuland Labs is listed on India’s National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558. For more information, visit www.NeulandLabs.com

#